Full Press Release Details
Altimmune Announces Submission of Investigational New Drug Application for AdCOVID a Single-dose Intranasal COVID-19 Vaccine; On Track to Commence Phase 1 Clinical Study in December.
ALT
Altimmune Announces Submission of Investigational New Drug Application for AdCOVID a Single-dose Intranasal COVID-19 Vaccine; On Track to Commence Phase 1 Clinical Study in December
Key Takeaway: Altimmune Announces Submission of Investigational New Drug Application for AdCOVID a Single-dose Intranasal COVID-19 Vaccine; On Track to Commence Phase 1 Clinical Study in December
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+22%
120-day peak, hindsight
Typical move
10.2%
average across 8 past catalysts
Cash runway
~64 mo
Minimal dilution risk
Lead asset
ALT-801
Phase 2 · Obesity/Overweight